Overall survival benefit for weekly vs. three-weekly taxanes regimens in advanced breast cancer: A meta-analysis

2010 ◽  
Vol 36 (1) ◽  
pp. 69-74 ◽  
Author(s):  
Davide Mauri ◽  
Konstantinos Kamposioras ◽  
Lamprini Tsali ◽  
Magdalini Bristianou ◽  
Antonis Valachis ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Overall Survival ◽  
Advanced Breast Cancer ◽  
Survival Benefit ◽  
Meta Analysis ◽  
Advanced Breast ◽  
Overall Survival Benefit

Efficacy of different anti-HER2 drugs in first-line therapy for advanced breast cancer: Systematic review and meta-analysis.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e11500-e11500
Author(s):  
Andre Deeke Sasse ◽  
Flavio Mavignier Carcano ◽  
Lucas Vieira dos Santos ◽  
Joao Paulo Da S.N. Lima
Keyword(s):  
Breast Cancer ◽  
Systematic Review ◽  
Overall Survival ◽  
Advanced Breast Cancer ◽  
Meta Analysis ◽  
Advanced Breast ◽  
First Line ◽  
First Line Therapy ◽  
Line Therapy ◽  
The Impact

e11500 Background: Anti-HER2 therapy has brought major gains to therapy of advanced breast cancer (ABC), however it is still not know if there are difference in efficacy between trastuzumab and lapatinib. We execute a systematic review and meta-analysis in order to measure the impact of anti-HER2 therapy on ABC outcome and to assess if any particular drug is more effective in this scenario. Methods: Randomized controlled trials comparing first-line antineoplastic drug plus minus antiHER2 therapy (either trastuzumab or lapatinib) in ABC patients were searched in major meeting proceedings and databases. The outcomes were overall survival (OS), progression-free survival (PFS), tumor response and safety. Meta-analyses were performed using random-effects model and outcomes measured by hazard ratio (HR) and pertinent 95% confidence intervals were calculated. Subgroup analyses and meta-regression were undertaken to compare and measure the impact of anti-HER2 drug used over the estimated effect size. Results: eight trials (1848 patients) were included, two trials used lapatinib whereas six used trastuzumab. In two trials, anti-HER2 therapy was combined to hormone therapy. All trials, except the one by Slamon, demanded tumors to be ISH+ or IHC 3+. The methodological quality of included trials was moderate to good. Either trastuzumab or lapatinib improved overall survival (HR 0.79; 95% CI 0.69-0.91; P=0.0008; I2=0%) with no difference bet drugs (test for difference P=0.75). PFS was also increased with antiHER2 addition with similar activity of trastuzumab and lapatinib (HR = 0.58; 95% CI 0.51-0.66; P<0.0001; I2=0%, test for difference P= 0.42). Conclusions: The present meta-analysis confirmed the role of antiHER2 drugs as a valid first-line therapy for ABC. Furthermore, we failed to show any difference in efficacy between lapatinib and trastuzumab when combined to systemic therapy, both being acceptable options for antiHER2 therapy for ABC.

Sign in / Sign up

Export Citation Format

Share Document